Pierre Fabre and Iktos Partner for AI-Driven Cancer Drug Discovery Initiative

Introduction to the Collaboration

On January 9, 2026, Pierre Fabre Laboratories and Iktos unveiled a groundbreaking collaboration focused on integrating advanced artificial intelligence in the realm of oncology drug discovery. This partnership aims to expedite the innovation process of novel small-molecule therapeutics, signaling a major leap forward in the fight against cancer. With each organization bringing unique strengths to the table, this alliance is poised to make significant contributions to precision medicine.

Goals of the Partnership

This collaboration is not merely a contractual agreement; it represents a shared vision for enhancing oncology treatments. Under this partnership, Iktos will utilize its pioneering AI-driven generative design platform. The objective is to fast-track the discovery of optimized small-molecule candidates targeting a specific oncology focus, which remains undisclosed for now. Pierre Fabre, well-regarded for its depth of expertise in oncology research and preclinical development, will guide the selection and progression of these candidate molecules, ensuring a robust evaluation process.

Financial Agreement Details

While specific financial terms have not been disclosed, the collaboration includes an upfront payment along with milestone payments contingent on progress. This allows both companies to align their interests closely with the successful advancement of candidates through the development pipeline.

Quotes from Leadership

Audrey Kauffmann, Head of Data Science and Biometry at Pierre Fabre Medical Care RD, remarked on the significance of this collaboration, stating, "This partnership marks a pivotal progression in our journey toward establishing an AI-centric R&D engine at Pierre Fabre Laboratories." She expressed optimism that the integration of Iktos' generative AI technology could immensely boost the overall quality and speed of the drug discovery process.

Olivier Geneste, Head of Drug Discovery at Pierre Fabre Medical Care RD, echoed similar sentiments, emphasizing the potential of Iktos' capabilities in generative AI and automated chemistry to mitigate risks associated with drug discovery. This should enable rapid development of therapeutics that address unmet needs in oncology.

Yann Gaston-Mathé, Co-founder and CEO of Iktos, expressed enthusiasm, acknowledging Pierre Fabre's distinguished history in oncology. He believes that merging Iktos‘ generative AI and automated chemistry with Pierre Fabre's scientific insight will create a powerful collaboration aimed at quickly bringing forth innovative therapies to patients worldwide.

Pierre Fabre’s Oncology Pipeline

Pierre Fabre Laboratories continues to expand its Precision Oncology efforts, having enriched its R&D pipeline with several promising assets. The company is actively developing mutant-selective EGFR inhibitors, targeted at treating non-small cell lung cancer (NSCLC), while also exploring options for solid tumors influenced by MET genetic alterations. The pan-RAF inhibitor, exarafenib, stands out as part of their expanding targeted therapy portfolio aimed at RAS/RAF-driven solid tumors.

In strategic collaboration with other entities, such as Vernalis Ltd. and RedRidge Bio, Pierre Fabre seeks to uncover and develop novel therapeutics, demonstrating a comprehensive approach to advancing cancer care. This new alignment with Iktos is expected to enhance their capabilities in generating drug candidates tailored to addressing various oncology targets.

About Pierre Fabre Laboratories

Pierre Fabre Laboratories ranks as the second-largest player in the global dermo-cosmetics market, complemented by a strong pharmaceutical lab presence in Europe. The company emphasizes its commitment to oncology, as evidenced by its revenues, with €520 million attributed to oncology sales in 2024 — a remarkable 88% derived from international markets. With a robust R&D budget geared towards research and development of targeted therapies, Pierre Fabre illustrates a steadfast commitment to pioneering innovations that can make significant impacts in patient’s lives.

About Iktos

Founded in 2016, Iktos stands at the forefront of AI and robotics, specifically tailored for drug discovery. The company’s AI-driven generative design platform not only streamlines the molecular design process but also integrates automated synthesis and biological testing. With over 60 successful projects under its belt, Iktos is aggressively advancing its pipeline across various therapeutic areas, including oncology, obesity, and autoimmune diseases. This rich portfolio further establishes Iktos as a key player in revolutionizing the future of drug discovery.

Conclusion

The collaboration between Pierre Fabre Laboratories and Iktos signifies a pivotal moment in the oncology landscape. By harnessing the power of AI, both organizations aim not only to advance their own research but also to set new standards in drug discovery that can efficiently deliver promising therapeutics to the patients who need them most. This collaboration reflects an innovative approach to tackling the pressing challenges within oncology and underlines their commitment to transformative patient outcomes.